GlassScriptPhysician profile
Alan P Broussard
NPI 1700874468
$1,720.30
in general payments reported to CMS, 2019-2025
22 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2021: $92.16 · 2022: $346 · 2023: $335 · 2024: $268 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,005.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $315.80 | 2023-2025 | Evenity, Prolia |
| Astellas Pharma US INC | $208.44 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.02 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $169.54 | 2019-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $127.93 | 2019-2022 | |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Teva Pharmaceuticals USA, INC. | $84.53 | 2019 | |
| Janssen Biotech, INC. | $70.31 | 2025 | Tremfya, Simponi Aria |
| Janssen Pharmaceuticals, INC | $61.29 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $45.56 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $43.13 | 2024-2025 | |
| Mylan Specialty L.P. | $38.30 | 2024 | Yupelri |
| Global Blood Therapeutics, INC. | $36.71 | 2021-2022 | |
| Dynavax Technologies Corporation | $31.54 | 2022-2025 | Heplisav-B |
| Lundbeck LLC | $27.77 | 2025 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.28 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $23.26 | 2024 | Crysvita |
| Dexcom, INC. | $22.83 | 2025 | Dexcom G6 Transmitter |
| Phadia US INC. | $19.03 | 2022 | |
| Abbott Laboratories | $16.73 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $15.14 | 2024 | |
| Lilly USA, LLC | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.